Conference Day One
8:00 am Check-In & Morning Coffee
8:50 am Chair’s Opening Remarks
Uncovering Different Perspectives on Model Selection Criteria to Develop a Consensus & Supercharge Oncology Drug Development
9:00 am Choosing the Best Humanized Mouse Model to Empower Drug Discovery
Synopsis
- Highlighting the rationale behind selecting the model
- Discussing methods to recreate key components of the tumor microenvironment
- Spotlighting data indicating the translational relevance of remodeled mouse models in predicting clinical outcomes and guiding the development of novel therapies
9:30 am Spotlighting Lessons Learned from Employing in vivo Models to Enhance Targeted Small Molecules Through to Cell Therapy Development
Synopsis
- Uncovering the rationale behind selection the models
- Discussing the commonalities and difference when it comes to model selection across different modalities like small molecules, radioligands to cell therapies
- Employing this knowledge to empower the development of different cell therapy modalities
10:00 am Speed Networking
Synopsis
As the Tumor Models community is reunited, this valuable session will ensure you get the chance to reconnect with peers and make brand new connections! This structured networking opportunity will pair you with fellow attendees for several 3-minute introductions, ensuring you have the opportunity to meet and network with your academic and industry colleagues.
10:30 am Morning Break & Networking Drug
Drug Discovery & Screening
Track Chair: Suchismita Mohanty, Senior Scientist, ArsenalBio
11:00 am Leveraging a Transwell Co-Culture Model to Inform Imvax’s Goldspire® Platform Development
Synopsis
- Sharing strategies to leverage a co-culture model to evaluate immune responses in an ex vivo context
- Overcoming challenges with optimizing this model for vaccine development
- Uncovering the translational relevance of this model to treat sold tumors
11:30 am Session Reserved for
Efficacy Evaluation & Biomarker Discovery
Track Chair: Hongyu Xue Director, In Vivo Pharmacology & Oncology Research Bayer
11:00 am Determining Activity of ADC + IO Combinations Through Preclinical Tumor Models
Synopsis
- Considerations when developing immunocompetent models to study ADC activity
- Syngeneic v humanized models – rationale and challenges
- Optimizing clinical relevance – dose and schedule selection
11:30 am Session Reserved for
12:00 pm Lunch Break
Drug Discovery & Screening
Track Chair: Suchismita Mohanty, Senior Scientist, ArsenalBio
1:00 pm Spotlighting Strategies to Develop in vivo Models to Support Ras Drug Development
Synopsis
- Model selection rationale
- Characterization of complex multi-parametric human tumor microenvironment
- Robustness of model system to correlate the human clinical trial data
1:30 pm Roundtable Discussion: Reverse Translation: Unlocking Precision Medicine Through Clinical Data
Synopsis
- How far have we come in bedside-to-benchtop research?
- How can clinical data robustly connect human immune data with in vivo models?
- Uncovering future uses of reverse translation to transform approaches to precision medicine
Efficacy Evaluation & Biomarker Discovery
Track Chair: HongyuXue Director, In Vivo Pharmacology & Oncology Research Bayer
1:00 pm Leveraging Humanized Mouse Models to Support T-Cell Engager Development
Synopsis
- Selection rationale for humanized mouse models including PBMCs, transgenic and tox models (pros/cons for TCEs)
- Case study evaluating T cell engagers with additional functionality
- Strategies for addressing TCE tolerability in vivo
1:30 pm Leveraging Preclinical Tumor Models to Aid Targeted Cytokine Therapy
Synopsis
- Understanding the rationale behind choosing the tumor models in this study
- Evaluating tumor efficacy and toxicity in mouse models to assess tumor response to treatment
- Combination dosing strategies of the IL-2 variant with bispecifics and CAR-T therapies
2:00 pm Scientific Poster Session & Refreshments Break
Interrogating Different Model Selection Criteria for Different Indications & Modalities & Employing Digital Pathology to Better Understand Your Preclinical Models
3:00 pm Session Reserved for Certis
3:30 pm Panel Discussion: How Do You Choose the Right Tumor Model for Your Preclinical Study?
Synopsis
- Uncovering perspectives from various targets, a range of underlying biology, and multiple therapeutic modalities
- What are you finding challenging to model in mice?
- Lessons learned dealing with costs rising, internalizing vs externalizing studies, resources and availability of tool molecules, and other logistical challenges
Moderated by: Stephanie Casey Parks
4:00 pm Session reserved for GenOway
4:30 pm Building a Gold Standard to Implement Digital Pathology in Oncology Drug Development
Synopsis
- Best practice to harness spatial biology tools including transcriptomics/proteomics/multiomics to improve understanding of your data read-outs
- Leveraging spatial data to refine patient stratification methods and enhance the design of future clinical trials for improved treatment outcomes